VRTX · News · 20260825N

Litigation and Legal Risk

VERTEX PHARMACEUTICALS INC / MA · 2026-08-25 · Importance 40 · Surprise 42

A federal judge ruled that Lupin’s proposed generic versions of Vertex’s cystic fibrosis drug Kalydeco do not infringe four Vertex patents. The court dismissed Vertex’s infringement lawsuit after finding that its claims concerning an “about 80%” active-ingredient concentration were too vague and insufficiently defined. The ruling could increase generic-competition risk for Kalydeco, although the report did not disclose an associated revenue or earnings impact.

Key facts

• A federal judge ruled that Lupin Ltd.'s proposed generic versions of Vertex Pharmaceuticals Inc.'s cystic fibrosis drug, Kalydeco, do not infringe on four of Vertex's patents. source
• The court found that Vertex's claims regarding an "about 80%" concentration of the active ingredient were too vague and not sufficiently defined in their patents, leading to the dismissal of their infringement lawsuit. source